军事知识服务平台
慢性乙型肝炎患者获得功能性治愈后复发的影响因素分析
Analysis of factors influencing relapse following the achievement of a functional cure in patients with chronic hepatitis B
摘要 目的 探索影响慢性乙型肝炎(简称慢乙肝)功能性治愈患者复发的影响因素.方法 本研究纳入2019年6月至2023年12月期间在安徽医科大学第一附属医院和中国科学技术大学附属省立医院就诊的122例基线HBsAg≤1 500 IU/mL的慢乙肝功能性治愈患者,先通过单因素分析患者的基线特征,再按7∶3随机分为训练集(n=85)与验证集(n=37).基于训练集,采用多因素logistic回归识别独立预测因素并构建列线图模型.通过受试者工作特征曲线分析确定连续变量的最佳截断值,并采用Kaplan-Meier法评估组间累积复发率.模型的性能通过验证集的区分度、校准曲线及决策曲线进行综合评价.结果 多因素logistic分析确定了基线乙型肝炎表面抗原(hepatitis B virus surface antigen,HBsAg)水平、治疗结束时(end off treatment,EOT)HBsAb 水平及 EOT 乙型肝炎核心抗体(hepatitis B core antibody,HBcAb)定量(qHBcAb)水平为预测复发的影响因素.模型在训练集中展现出了良好的区分能力,曲线下面积(area under curve,AUC)为0.82;在独立验证集中,AUC为0.80,性能衰减轻微(2.4%).决策曲线分析表明该模型具有积极的临床净获益.Kaplan-Meier生存分析显示基线HBsAg≤92 IU/mL和HBsAg>92 IU/mL的累积复发概率分别为9.7%和36.0%.EOT HBsAb≤60 mIU/mL和EOT HBsAb>60 mIU/mL的累积复发概率分别为 9.5%和 32.3%.EOT qHBcAb≤1 010 IU/mL 和 EOT qHBcAb>1 010 IU/mL 的累积复发概率分别为43.3%和13.0%.结论 基线HBsAg≤92 IU/mL且治疗结束时HBsAb>60 mIU/mL、qHBcAb>1 010 IU/mL的CHB功能性治愈患者复发率较低.
Abstract:
Objective To explore the factors influencing relapse in patients with functional cure of chronic hepatitis B(CHB).Methods A total of 122 patients with functional cure of CHB with baseline HBsAg≤1 500 IU/mL were collected from the First Affiliated Hospital of Anhui Medical University and the Provincial Hospital Affiliated to University of Science and Technology of China from June 2019 to December 2023.The baseline characteristics of the patients were first analyzed by univariate analysis,and then they were randomly divided into a training set(n=85)and a validation set(n=37)at a ratio of 7∶3.Based on the training set,multivariate logistic regression was used to identify independent predictive factors and construct a nomogram model.Receiver operating characteristic curve analysis was used to determine the optimal cutoff value of continuous variables,and Kaplan-Meier method was used to assess cumulative recurrence rates between groups.Model performance was comprehensively evaluated by discriminative power,calibration curve and decision curve of the validation set.Results Multivariate logistic analysis identified baseline hepatitis B virus surface antigen(HBsAg)level,HBsAb level at end of treatment(EOT)and EOT quantitative HBcAb(qHBcAb)level as influencing factors predicting relapse.The model shows good discriminative ability in the training set,with an area under curve(AUC)of 0.82.In the independent validation set,the AUC is 0.80 with a minimal performance decline of 2.4%.Decision curve analysis shows the model has positive clinical net benefit.Kaplan-Meier survival analysis shows the cumulative recurrence probabilities are 9.7%and 36%for baseline HBsAg≤92 IU/mL and HBsAg>92 IU/mL,respectively.The cumulative recurrence probabilities are 9.5%and 32.3%for EOT HBsAb≤60 mIU/mL and EOT HBsAb>60 mIU/mL,respectively.At EOT,the cumulative recurrence probabilities are 43.3%and 13%,respectively,for qHBcAb≤1 010 IU/mL and qHBcAb>1 010 IU/mL.Conclusion CHB patients with functional cure have a low relapse rate if they have baseline HBsAg≤92 IU/mL,HBsAb>60 mIU/mL at the end of treatment and qHBcAb>1 010 IU/mL.
刊 名 中国病毒病杂志 ISTIC
年,卷(期): 2026, 16(2)
分类号: R373
机标分类号: R512.62 R195.4 R735.7
在线出版日期: 2026年7月2日
基金项目: 82370608:国家自然科学基金2022AH040160:安徽省高校自然科学研究项目202304295107020040:安徽省临床医学研究转化专项基金FY2023-122:阜阳市卫健委青年项目,